HMCIB SPAC 3 (226340) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HMCIB SPAC 3 (226340) has a cash flow conversion efficiency ratio of 0.042x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.56 Billion ≈ $1.73 Million USD) by net assets (₩60.89 Billion ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View 226340 share price today for real-time trading data and today's change.
HMCIB SPAC 3 - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how HMCIB SPAC 3's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 226340 company net worth for the company's overall valuation and market capitalisation.
HMCIB SPAC 3 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HMCIB SPAC 3 ranked by their cash flow conversion efficiency. Also see HMCIB SPAC 3 balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Conduent Inc
NASDAQ:CNDT
|
0.047x |
|
Legal & General Group PLC
LSE:LGEN
|
-1.135x |
|
SR Accord
TA:SRAC
|
-0.088x |
|
Yapi Kredi Koray Gayrimenkul Yatirim Ortakligi AS
IS:KGYO
|
-0.140x |
|
Nordic Aqua Partners As
OL:NOAP
|
-0.140x |
|
Pioneer Municipal High Income Advantage Trust
NYSE:MAV
|
0.017x |
|
SEEING MACHINES LTD
F:M2Z
|
N/A |
|
Bursa Cimento Fabrikasi AS
IS:BUCIM
|
0.017x |
Annual Cash Flow Conversion Efficiency for HMCIB SPAC 3 (2015–2023)
The table below shows the annual cash flow conversion efficiency of HMCIB SPAC 3 from 2015 to 2023. Review HMCIB SPAC 3 free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | ₩39.84 Billion ≈ $27.00 Million |
₩4.61 Billion ≈ $3.13 Million |
0.116x | +183.54% |
| 2022-12-31 | ₩25.63 Billion ≈ $17.37 Million |
₩-3.55 Billion ≈ $-2.41 Million |
-0.139x | -251.58% |
| 2021-12-31 | ₩22.41 Billion ≈ $15.18 Million |
₩2.05 Billion ≈ $1.39 Million |
0.091x | -0.20% |
| 2020-12-31 | ₩32.52 Billion ≈ $22.04 Million |
₩2.98 Billion ≈ $2.02 Million |
0.092x | -68.80% |
| 2019-12-31 | ₩33.96 Billion ≈ $23.01 Million |
₩9.98 Billion ≈ $6.76 Million |
0.294x | +230.09% |
| 2018-12-31 | ₩24.80 Billion ≈ $16.81 Million |
₩-5.60 Billion ≈ $-3.80 Million |
-0.226x | -194.68% |
| 2017-12-31 | ₩12.67 Billion ≈ $8.59 Million |
₩3.02 Billion ≈ $2.05 Million |
0.239x | +1674.08% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
₩168.86 Million ≈ $114.43K |
0.013x | +174.41% |
| 2015-12-31 | ₩12.40 Billion ≈ $8.41 Million |
₩-224.16 Million ≈ $-151.91K |
-0.018x | -- |
About HMCIB SPAC 3
Bonne Co., Ltd. develops and supplies cosmetics in South Korea. The company offers skin care products, including whitening, wrinkle and pimple treatment, stem-cell peptide, and nano peptide products; and sun care products comprising fluids, creams, emulsions, etc. It also provides hair and body care products; makeup products, such as foundation, powder, compact, loose powder, BB cream, eye liner,… Read more